Aura Biosciences Inc (AURA) AI Stock Analysis

• Market Cap: $355.62M
• Dividend Yield: N/A
• Average Volume (3M): 302.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.70
• Revenue Growth: N/A
• EPS Growth: -11.41%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 63,503,270
• 10 Day Avg. Volume: 325,525
• 30 Day Avg. Volume: 302,397
• PEG Ratio: 0.50
• Price to Book (P/B): 2.69
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.03
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -365.68
• Enterprise Value/Ebitda: -3.05
• 1Y Price Target: $19.33
• Price Target Upside: 245.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $5.00 ▼(-10.71% Downside)

The score is driven primarily by weak financial performance: no revenue, increasing losses, and significant ongoing cash burn despite relatively low leverage. Technicals add further pressure with the stock trading below major moving averages and a negative MACD, while valuation metrics offer limited support due to the negative P/E and no dividend yield.

Positive Factors

Cash Position

A strong cash position provides Aura Biosciences with the financial runway to continue its R&D efforts and clinical trials, supporting long-term growth and innovation.

Clinical Trials Progress

Progress in clinical trials, particularly the Phase 3 CoMpass trial, indicates potential future product approvals, which could significantly impact market position and revenue.

Pipeline Development

Advancements in the AU-011 study for bladder cancer highlight the company's commitment to expanding its therapeutic pipeline, potentially increasing its market reach and addressing unmet medical needs.

Negative Factors

Cash Burn

High cash burn rates indicate significant ongoing expenses without revenue generation, which could strain financial resources and necessitate further capital raising.

Widening Net Losses

Increasing net losses reflect rising operational costs and the absence of revenue, which could hinder financial stability and investor confidence in the long term.

Reliance on External Funding

Dependence on external funding due to declining equity/assets may limit strategic flexibility and increase vulnerability to market conditions, impacting long-term sustainability.

Aura Biosciences Inc Business Overview & Revenue Model

Company Description

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Aura Biosciences generates revenue primarily through the development and potential commercialization of its proprietary cancer therapies. The company aims to make money by obtaining regulatory approval for its drug candidates and subsequently commercializing them either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams may include upfront payments, milestone payments, and royalties from licensing agreements, as well as direct sales of approved therapies. Significant partnerships with established pharmaceutical companies can also contribute to its earnings by providing financial support and market access for its products.

Aura Biosciences Inc Financial Statement Overview

Summary

Pre-revenue profile with widening net losses (about -$86.9M in 2024; -$106.5M TTM) and deeply negative operating/free cash flow (operating cash flow about -$88.2M TTM). Balance sheet leverage is relatively low (debt-to-equity around ~0.10 TTM), but equity/assets have declined alongside ongoing cash burn, increasing reliance on external funding.

Income Statement

Aura Biosciences has no reported revenue across the annual periods provided and TTM (Trailing-Twelve-Months), which keeps profitability deeply negative and limits visibility into operating leverage. Losses have widened over time (net loss roughly -$22.2M in 2020 to about -$86.9M in 2024 and -$106.5M in TTM), indicating rising operating expenses ahead of commercialization. A modest positive is that the company is still in a build/invest phase typical for biotech, but the current trajectory shows increasing cash burn with no revenue base to offset it.

Balance Sheet

The balance sheet shows relatively low leverage, with debt modest versus equity (debt-to-equity around ~0.09–0.12 recently; ~0.10 in TTM), which reduces solvency risk. However, equity and total assets have declined from 2023 to TTM (equity down from ~$225.8M to ~$156.7M; assets down from ~$255.1M to ~$190.0M), consistent with ongoing losses and cash usage. Returns to shareholders remain strongly negative (return on equity about -0.57 in 2024 and -0.64 in TTM), highlighting that the company is consuming capital rather than generating it.

Cash Flow

Cash generation remains materially negative, with operating cash flow at about -$79.8M in 2024 and -$88.2M in TTM (Trailing-Twelve-Months), and free cash flow similarly negative (~- $81.1M in 2024; ~- $88.8M in TTM). The cash burn has generally increased versus earlier years (e.g., operating cash flow around -$32.4M in 2021 and -$54.6M in 2022), which raises financing dependence. While the latest period shows a positive free cash flow growth figure, free cash flow is still deeply negative overall, so liquidity will likely rely on external funding until revenue arrives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-891.00K	0.00	-1.29M	-1.18M	0.00	0.00
EBITDA	-106.74M	-94.89M	-83.70M	-59.12M	-34.42M	-21.38M
Net Income	-106.47M	-86.92M	-76.41M	-58.76M	-35.25M	-22.21M
Balance Sheet
Total Assets	190.02M	182.50M	255.07M	223.94M	160.03M	22.10M
Cash, Cash Equivalents and Short-Term Investments	161.87M	151.09M	226.15M	188.81M	149.06M	17.39M
Total Debt	17.75M	18.77M	19.56M	20.86M	975.00K	15.00K
Total Liabilities	33.36M	30.53M	29.23M	28.35M	7.71M	2.74M
Stockholders Equity	156.67M	151.97M	225.85M	195.58M	152.31M	19.36M
Cash Flow
Free Cash Flow	-88.80M	-81.06M	-64.56M	-55.70M	-34.53M	-25.09M
Operating Cash Flow	-88.22M	-79.81M	-63.85M	-54.60M	-32.41M	-24.32M
Investing Cash Flow	35.47M	68.82M	-113.96M	-67.87M	-2.13M	-771.00K
Financing Cash Flow	74.93M	1.59M	97.29M	95.63M	166.26M	10.04M

Aura Biosciences Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AURA, the sentiment is Neutral. The current price of 5.6 is above the 20-day moving average (MA) of 5.32, below the 50-day MA of 5.73, and below the 200-day MA of 6.07, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 52.46 is Neutral, neither overbought nor oversold. The STOCH value of 66.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AURA.

Aura Biosciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANNX	56 Neutral	$903.11M	―	-83.98%	―	―	-35.62%
DSGN	55 Neutral	$581.60M	-8.60	-29.83%	―	―	-40.26%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASMB	49 Neutral	$407.69M	-5.37	-36.94%	―	31.30%	32.79%
KRRO	49 Neutral	$125.53M	-1.42	-63.46%	―	―	21.61%
FDMT	47 Neutral	$451.93M	-2.25	-45.38%	―	―	―
AURA	42 Neutral	$355.62M	-2.90	-64.26%	―	―	-11.41%

Aura Biosciences Inc Corporate Events

Aura Biosciences Reports Q3 2025 Financial Results

On November 13, 2025, Aura Biosciences reported its third-quarter financial results and business highlights, emphasizing its focus on clinical execution in trials for early choroidal melanoma and non-muscle invasive bladder cancer (NMIBC). The company announced that enrollment for the Phase 3 CoMpass trial in early choroidal melanoma is expected to complete in 2026, with topline data anticipated in late 2027. The Phase 1b/2 trial for NMIBC is on track, with data expected in mid-2026. Aura Biosciences also highlighted the potential of bel-sar to transform treatment paradigms in ocular and urologic oncology, aiming to address high unmet medical needs with its innovative therapies.

The most recent analyst rating on (AURA) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.